Pfizer Inc. PFE named oncology chief and company veteran Chris Boshoff as its new chief scientific officer on Wednesday, replacing Mikael Dolsten starting Jan. 1. The drug company had been ...

He is replacing Dr Mikael Dolsten whose departure from Pfizer was announced in July, bringing a 15-year-plus career at the pharma group to a close, effective 1st January. The shake-up in Pfizer's ...

On Thursday, Pfizer’s Dr. Mikael Dolsten told The Associated Press that early data from the company’s booster study suggests people’s antibody levels jump five- to 10-fold after a third dose ...

Dr. Boshoff, who most recently served as Chief Oncology Officer and Executive Vice President, will succeed Dr. Mikael Dolsten whose departure from Pfizer was announced earlier this year.

According to the group’s soon-to-depart chief scientific officer, Mikael Dolsten, Pfizer has a “robust pipeline” of three clinical and several preclinical candidates. While danuglipron has ...

and we are pleased to be able to further enhance our leadership position in this area through this unique fellowship program,” said Mikael Dolsten, M.D., Ph.D., president of worldwide research and ...

But BridgeBio’s challenges aren’t over. The biotech’s new product must now compete against a blockbuster Pfizer medication already well established as the standard of care and fend off new ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Pfizer (PFE – Research Report), with a price target of $31.00. The company’s shares opened today at ...

Is Pfizer stock a sell after shares skidded on the news Trump selected Kennedy to take over HHS? Is PFE stock now a sell?